Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Jaguar Health Inc. (JAGX:NASDAQ), powered by AI.
Jaguar Health Inc. is currently trading at $2.31. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Jaguar Health Inc. on Alpha Lenz.
Jaguar Health Inc.'s P/E ratio is -0.1.
“Jaguar Health Inc. trades at a P/E of -0.1 (undervalued) with strong ROE of 1068.3%.”
Ask for details →Jaguar Health Inc. is a commercial-stage pharmaceuticals and biotechnology company that focuses on the development and commercialization of novel plant-based prescription medicines. The primary purpose of Jaguar Health is to address health issues in both humans and animals, thereby playing a crucial role in the biopharmaceutical industry. Known for its commitment to improving global health standards, Jaguar Health emphasizes the development of effective digestive health medications, often derived from naturally occurring sources. The company is particularly noted for its work in creating treatments aimed at chronic, debilitating conditions such as diarrhea in human populations, including those in resource-constrained settings. Jaguar Health's subsidiaries and collaborations allow it to expand its reach and impact across various markets, emphasizing innovation within the realms of botanical sciences and pharmaceuticals. In the financial market, Jaguar Health Inc. garners attention for its unique position at the intersection of natural medicine and pharmaceutical technology, appealing to investors interested in both health innovation and sustainable medicinal approaches. As such, Jaguar Health holds a distinctive role within the global healthcare sector.
“Jaguar Health Inc. trades at a P/E of -0.1 (undervalued) with strong ROE of 1068.3%.”
Ask for details →Jaguar Health Inc. (ticker: JAGX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 49 employees. Market cap is $5M.
The current price is $2.31 with a P/E ratio of -0.1x and P/B of -0.31x.
ROE is 1068.25% and operating margin is -391.87%. Annual revenue is $12M.